Clinical Trial Detail

NCT ID NCT03191786
Title A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naive Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy (IPSOS)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

lung non-small cell carcinoma

Therapies

Atezolizumab

Gemcitabine

Vinorelbine

Age Groups: adult senior

Additional content available in CKB BOOST